Targeted diagnostics Potential sales opportunity in expanding adoption of ASTar beyond hospital settings to regional labs and outpatient facilities that handle positive blood cultures, leveraging its rapid six hour turnaround to reduce broad-spectrum antibiotic use and shorten patient treatment timelines.

Regulatory readiness Leverage Q-linea's CE-IVD certification and US-FDA clearance to pursue parallel trials or expansions in markets with stringent regulatory requirements, positioning ASTar as a validated, compliant solution for antimicrobial susceptibility testing.

Clinical impact Highlight hospital and health system value propositions around accelerated pathogen identification and optimized antimicrobial therapy, offering case-based ROI analytics to convert procurement committees and ID physicians.

Strategic partnerships Identify opportunities with radiating suppliers and distributors of infectious disease diagnostics and with hospitals leveraging similar platforms from QIAGEN or Cepheid to cross-sell integration capabilities, service packages, and training.

Growth readiness Expand sales outreach to mid-sized and larger healthcare systems (the firm’s revenue range suggests scalability beyond small clinics) with tailored pilots, bundled service agreements, and scalable implementation plans using existing tech stack and cloud hosting capabilities.